New protein test could spot hidden uterine disease
NCT ID NCT06864494
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at whether a protein called L-PGDS can be used to diagnose adenomyosis, a condition where uterine tissue grows into the muscle wall, causing pain and heavy bleeding. Researchers will measure L-PGDS levels in vaginal swabs, blood, and urine from 60 women with and without adenomyosis. If L-PGDS levels differ between groups, it might lead to a simple, non-invasive diagnostic test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple, non-invasive diagnostic test for adenomyosis using blood or urine, potentially catching the disease earlier.
What could go wrong
This is a small, early-stage study (60 participants) that only measures a protein level. It may not prove useful for diagnosis, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOMYOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nimes
RECRUITINGNîmes, 30029, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact